Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (449) Arrow Down
Filter Results: (449) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (637)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)

Show Results For

  • All HBS Web  (637)
    • People  (2)
    • News  (57)
    • Research  (449)
    • Events  (2)
    • Multimedia  (8)
  • Faculty Publications  (395)
← Page 11 of 449 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • August 1996 (Revised May 1997)
  • Case

Delta & Pine Land: Measuring the Value of Transgenic Cotton

By: Ray A. Goldberg and Charlotte A. Tasker
Discusses the joint venture between two companies with different capabilities: 1) technology provider and 2) transportation agent. Discusses how to capture value from joint venture and biotechnology: 1) who are winners and who are losers; 2) how much value can/should... View Details
Keywords: Agribusiness; Joint Ventures; Marketing Strategy; Supply Chain Management; Performance Consistency; Information Technology; Transportation; Valuation; Biotechnology Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., and Charlotte A. Tasker. "Delta & Pine Land: Measuring the Value of Transgenic Cotton." Harvard Business School Case 597-005, August 1996. (Revised May 1997.)
  • November 1995 (Revised February 1996)
  • Case

Monsanto Company: The Coming of Age of Bio-Technology

By: Ray A. Goldberg and Thomas N. Urban Jr
Monsanto has one product, Roundup, accounting for 30% of company net income and is going off patent. How should the company position itself and its products in the future? View Details
Keywords: Patents; Product Positioning; Strategic Planning; System Shocks; Biotechnology Industry
Citation
Educators
Purchase
Related
Goldberg, Ray A., and Thomas N. Urban Jr. "Monsanto Company: The Coming of Age of Bio-Technology." Harvard Business School Case 596-034, November 1995. (Revised February 1996.)
  • November 1978 (Revised October 1989)
  • Case

Amicon Corp. (B)

Details the negotiation between Amicon and three potential licensees, Jackson, Maynard-Smith and Behrstein. View Details
Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry
Citation
Educators
Purchase
Related
Capon, Noel. "Amicon Corp. (B)." Harvard Business School Case 579-094, November 1978. (Revised October 1989.)
  • November 2010 (Revised July 2012)
  • Teaching Note

Arcadia Biosciences: Seeds of Change (TN)

By: Arthur A. Daemmrich and Forest L. Reinhardt
Teaching Note for 709019. View Details
Keywords: Biotechnology Industry
Citation
Purchase
Related
Daemmrich, Arthur A., and Forest L. Reinhardt. "Arcadia Biosciences: Seeds of Change (TN)." Harvard Business School Teaching Note 711-042, November 2010. (Revised July 2012.)
  • July 1993
  • Case

Genzyme Corporation: A Financing History

By: Timothy A. Luehrman and Andrew D. Regan
Genzyme Corp.'s financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product--market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the... View Details
Keywords: History; Marketing Strategy; Financing and Loans; Business Strategy; Growth and Development Strategy; Biotechnology Industry
Citation
Educators
Purchase
Related
Luehrman, Timothy A., and Andrew D. Regan. "Genzyme Corporation: A Financing History." Harvard Business School Case 294-005, July 1993.
  • July 2023
  • Case

Moderna: Everything, Everywhere, All at Once

By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold... View Details
Keywords: Health Pandemics; Selection and Staffing; Growth Management; Management Succession; Retirement; Technological Innovation; Corporate Strategy; Biotechnology Industry
Citation
Educators
Purchase
Related
Tadikonda, Satish, Shikhar Ghosh, and William Marks. "Moderna: Everything, Everywhere, All at Once." Harvard Business School Case 824-021, July 2023.
  • November 2016
  • Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Citation
Educators
Purchase
Related
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
  • 2009
  • Case

Innovamedica: Innovation in an Emerging Market

By: Roberto Charvel, Fernando Fabre and T. Putimahtama
Innovamedica was a medical start up with several state of the art devices such as a silicon substitute heart and other inventions. However, the founding scientist was struggling in attracting talent and fundraising and that had an impact on growth. View Details
Keywords: Biotech; Entrepreneurial Finance; Entrepreneurship; Start-up; Emergent Countries; Business Startups; Talent and Talent Management; Design; Corporate Entrepreneurship; Private Equity; Health Testing and Trials; Innovation and Invention; Managerial Roles; Biotechnology Industry; Latin America; North and Central America
Citation
Related
Charvel, Roberto, Fernando Fabre, and T. Putimahtama. "Innovamedica: Innovation in an Emerging Market." Instituto Panamericano de Alta Dirección de Empresa (IPADE) Case (P)DGe-440, 2009.
  • March 2012 (Revised October 2013)
  • Supplement

Gene Patents (B)

By: Richard Hamermesh and Phillip Andrews
The case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major... View Details
Keywords: Courts and Trials; Patents; Genetics; Judgments; Investment; Biotechnology Industry; United States
Citation
Purchase
Related
Hamermesh, Richard, and Phillip Andrews. "Gene Patents (B)." Harvard Business School Supplement 812-130, March 2012. (Revised October 2013.)
  • January 2010
  • Supplement

Genzyme's CSR Dilemma: How to Play its HAND - video supplement

By: Tarun Khanna and Christopher A. Bartlett
Keywords: Biotechnology Industry
Citation
Purchase
Related
Khanna, Tarun, and Christopher A. Bartlett. "Genzyme's CSR Dilemma: How to Play its HAND - video supplement." Harvard Business School Video Supplement 910-801, January 2010.
  • January 2010 (Revised November 2012)
  • Teaching Note

Genzyme's CSR Dilemma: How to Play its HAND (TN)

By: Christopher A. Bartlett
Teaching Note for [910407]. View Details
Keywords: Programs; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Multinational Firms and Management; Competitive Strategy; Markets; Biotechnology Industry
Citation
Purchase
Related
Bartlett, Christopher A. "Genzyme's CSR Dilemma: How to Play its HAND (TN)." Harvard Business School Teaching Note 910-414, January 2010. (Revised November 2012.)
  • October 2009 (Revised August 2014)
  • Case

Tengion: Bringing Regenerative Medicine to Life

By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Citation
Educators
Purchase
Related
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
  • February 2008 (Revised August 2008)
  • Case

EXACT Sciences Corp.: Commercializing a Diagnostic Test

By: Regina E. Herzlinger
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test. View Details
Keywords: Health Testing and Trials; Genetics; Science-Based Business; Commercialization; Biotechnology Industry
Citation
Find at Harvard
Related
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
  • June 2004 (Revised November 2004)
  • Case

Acorda Therapeutics: Rebuilding the Spinal Cord

Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details
Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry
Citation
Find at Harvard
Related
Enriquez-Cabot, Juan, Jonathan West, Marina Kolesnik, and Fiona Murray. "Acorda Therapeutics: Rebuilding the Spinal Cord." Harvard Business School Case 604-014, June 2004. (Revised November 2004.)
  • October 1997
  • Case

Roslin Institute, The

By: Ray A. Goldberg and Tom Clay
Dr. Ian Willmut and the Roslin Institute have developed a revolutionary new technology--cloning. Now they are faced with some tough choices concerning going forward. How should they balance commercialization opportunities with societal concerns? View Details
Keywords: Decision Choices and Conditions; Independent Innovation and Invention; Social Issues; Commercialization; Biotechnology Industry
Citation
Find at Harvard
Related
Goldberg, Ray A., and Tom Clay. "Roslin Institute, The." Harvard Business School Case 598-045, October 1997.
  • November 1986
  • Case

Amgen

By: Ray A. Goldberg
Keywords: Biotechnology Industry
Citation
Find at Harvard
Related
Goldberg, Ray A. "Amgen." Harvard Business School Case 587-095, November 1986.
  • 26 Jul 2016
  • Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Biotechnology; Biotechnology; Biotechnology
  • 21 Apr 2014
  • Research & Ideas

Bio-Piracy: When Western Firms Usurp Eastern Medicine

In May 1995, two scientists at the University of Mississippi were granted an American patent for the use of turmeric to treat flesh wounds. Soon thereafter, an Indian research organization won a lawsuit challenging the novelty of the patent. As it turned out, Indians... View Details
Keywords: by Carmen Nobel; Biotechnology; Biotechnology
  • 07 Feb 2005
  • Research & Ideas

How “Career Imprinting” Shapes Leaders

Abbott's career imprint could be called a "functional career imprint." Baxter generated a disproportionate number of leaders in the biotechnology industry. During the early 1980s, when the biotech industry was just heating up... View Details
Keywords: by Mallory Stark
  • 10 Aug 2020
  • Research & Ideas

COVID's Surprising Toll on Careers of Women Scientists

COVID-19 is claiming an unexpected career toll among scientific researchers, and particularly on women, new research shows. If you are female, have young children, or work in a lab, you are more likely to feel the career-crunching effects dealt by the pandemic,... View Details
Keywords: by Rachel Layne; Biotechnology; Biotechnology; Biotechnology
  • ←
  • 11
  • 12
  • …
  • 22
  • 23
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.